Table 1

The association of HHLA2 expression level with clinicopathological characteristics in the training cohort and validation cohort

Variables	Training cohort (n=206)				Validation cohort (n=197)
	Patients, n	HHLA2 expression			Patients, n	HHLA2 expression
	Patients, n	Negative	Positive	P value	Patients, n	Negative	Positive	P value
Age (y)				0.619				0.254
<53	90	52	38		102	64	38
≥53	116	63	53		95	52	43
Gender				0.409				0.11
Male	134	72	62		141	88	53
Female	72	43	29		56	28	28
Necrosis				0.001				0.001
Absent	149	94	55		151	99	52
Present	57	21	36		46	17	29
MVI				0.035				0.148
Absent	179	105	74		169	103	66
Present	27	10	17		28	13	15
Fuhrman grade				< 0.001				0.032
Low1 2	136	93	43		129	83	46
High3 4	70	22	48		68	33	35
TNM stage				< 0.001				0.008
Low (I, II)	146	94	52		146	94	52
High (III, IV)	60	21	39		51	22	29
PD-L1				0.003				0.002
Negative	138	87	51		134	89	45
Positive	68	28	40		63	27	36

*P values <0.05 in bold are statistically significant.
HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; MVI, microvascular invasion; PD-L1, programmed death 1 ligand 1.